1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The purpose of this Notice of Funding Opportunity (NOFO) is to support SenNet Discovery and Validation Centers (SenNet DVCs) as a core component of Stage 2 of the NIH Common Fund Cellular Senescence Network (SenNet). Building on Stage 1 resources, DVCs will define, refine, and validate tissue- and disease-relevant cellular senescence signatures (“senotypes”) and associated biomarkers, and will investigate their functional consequences in human health and disease. DVCs are expected to generate and contribute high-quality molecular, cellular, and spatial datasets (including relevant metadata and documentation) and to use complementary experimental systems, as appropriate, to validate senotypes/biomarkers and characterize responses to senescence-associated perturbations or senotherapeutic approaches. DVC applications should also propose goals and aims for SenNet consortium-wide organizational and outreach activities (SenNet OOC functions).
Funding Opportunity Number: RFA-RM-27-016. Assistance Listing: 93.310. Funding Instrument: CA. Category: HL.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). Confirm the full requirements in the official notice before applying.
Applications for Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed) are due November 23, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Applications for a 3-year extension/renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) clinical trial consortium are requested to fully meet the enrollment targets, complete participant follow-up, and finalize data analysis and dissemination of study findings. This Notice of Funding Opportunity (NOFO) invites a Single Source application for the eligible organization, the Scientific and Data Research Center (SDRC) already involved in the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors. Funding Opportunity Number: RFA-DK-27-139. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: $1.8M total program funding.
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from the eligible organization to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, applications will be peer-reviewed, and only meritorious applications will be considered for funding. Through this NOFO, the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites an application to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement that addresses specific knowledge gaps in the development and progression of type 1 diabetes complications. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples. Funding Opportunity Number: RFA-DK-27-112. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: $6.3M total program funding.
NIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read article